Results 1 to 10 of about 8,939 (128)

Essential Thrombocythemia [PDF]

New England Journal of Medicine, 2020
na
Elisa, Rumi, Mario, Cazzola
  +8 more sources

Essential thrombocythemia [PDF]

Orphanet Journal of Rare Diseases, 2007
Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age.
openaire   +5 more sources

Thrombospondin in essential thrombocythemia [PDF]

Blood, 1986
Abstract Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the ...
J, Lawler, A M, Cohen, F C, Chao, D J, Moriarty   +3 more
openaire   +3 more sources

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo, Barbui, Tiziano, Beggiato, Eloise, Bellini, Marta, Bertozzi, Irene, Betti, Silvia, Bonifacio, Massimiliano, Cacciola, Emma, Cacciola, Rossella, Carli, Giuseppe, Carobbio, Alessandra, Cattaneo, Daniele, Cazzola, Mario, Censori, Bruno, Cervantes, Francisco, Cortelezzi, Agostino, De Stefano, Valerio, Di Lazzaro, Vincenzo, Elli, Elena Maria, Ellis, Martin H., Finazzi, Guido, Finazzi, Maria Chiara, Gaidano, Gianluca, Gomez, Montse, Griesshammer, Martin, Guglielmelli, Paola, Hernandez-Boluda, Juan-Carlos, Iurlo, Alessandra, Loscocco, Giuseppe Gaetano, Lunghi, Francesca, Miroslava, Palova, Musolino, Caterina, Palandri, Francesca, Randi, Maria Luigia, Rapezzi, Davide, Rossi, Elena, Rumi, Elisa, Sadjadian, Parvis, Scaffidi, Luigi, Tieghi, Alessia, Vannucchi, Alessandro M., Vianelli, Nicola   +41 more
core   +5 more sources

Essential thrombocythemia (ET) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
The disease is a chronic myeloproliferative disorder originating from a mutated pluripotent stem cell capable of producing red blood cells, granulocytes and megakaryocytes. In some cases, B-lymphocyte involvement by the clonal proliferation was documented.
CUNEO, Antonio, CAVAZZINI, Francesco
openaire   +2 more sources

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [PDF]

, 2019
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with ...
Accurso V., Casimiro P., Contrino A. D., Di Piazza F., Perez A., Raso S., Russo A., Santoro M., Siragusa S.   +8 more
core   +1 more source

Patients with Essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis [PDF]

, 2002
A significant proportion of patients with Essential Thrombocythaemia (ET) have thrombotic complications which have an important impact upon the quality, and duration of their life.
Carr, P., Dave, M., Donohoe, S., Harrison, C.N., Machin, S.J., Mackie, I.   +5 more
core   +1 more source

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations [PDF]

, 2015
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Andrikovics, Hajnalka, Balassa, Katalin, Batai A, Bors, András, Csomor, Judit, Dolgos J, Egyed, Miklós, Halm G, Koszarska M, Krähling, Tünde, Masszi, Tamás, Remenyi P, Sipos A, Tordai, Attila   +13 more
core   +1 more source

Mouse models of myeloproliferative Neoplasms: JAK of all grades. (Review) [PDF]

, 2011
In 2005, several groups identified a single gain-of-function point mutation in the JAK2 kinase that was present in the majority of patients with myeloproliferative neoplasms (MPNs).
Li, J., Kent, D.G., Chen, E., Green, A.R., Li, J., Kent, D.G., Chen, E., Green, A.R.   +7 more
core   +2 more sources

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela, Marin Oyarzún, Cecilia Paola   +1 more
core   +1 more source